← Oncology Approval Tracker

FDA DECISION ·

Adcetris + AVE-PC

brentuximab vedotin plus doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide · Seagen

FDA approvalNew or expanded indicationClassical Hodgkin lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children age two or older with previously untreated high-risk classical Hodgkin lymphoma receiving brentuximab vedotin with the AVE-PC regimen.

LAMPGEN ANALYSIS

Why it matters

This adds a CD30-directed antibody-drug conjugate to frontline therapy for a defined high-risk pediatric population.

What research teams should watch

Confirm the pediatric risk category and coordinate chemotherapy administration and neuropathy monitoring.

PRIMARY RECORDS

Sources